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ABSTRAK
Respons imun pada demam dengue/demam berdarah dengue merupakan suatu rangkaian imunopatogenesis 
yang dimulai sejak target infeksi virus terhadap monosit dan makrofag. Selanjutnya akan menimbulkan suatu 
kaskade  dari viremia di sirkulasi yang menstimulasi mekanisme aferen, mekanisme eferen dan mekanisme efektor 
melalui interaksi dengan berbagai sistem humoral dan komplemen. Substansi inflamasi yang dihasilkan akan 
mempengaruhi permeabilitas kapiler dan mengaktivasi faktor koagulasi serta berpengaruh terhadap kerja tingkat 
endotel. Mekanisme yang melibatkan patogenesis DBD/DSS masih belum jelas. Selama ini  berkembang teori 
infeksi heterologus infection, dimana pada infeksi kedua kalinya terjadi sub netralisasi yang memicu replikasi 
virus. Mekanisme autoimun merupakan suatu proses autoimun yang dapat memperkaya kazanah pemahaman 
DBD. Mekanisme autoimun tersebut, menjelaskan respons autoimun oleh infeksi virus  yang terdiri dari molecular 
mimicry, bystander activation dan viral persistence. Patomekanisme auto imun ini berkembang terkait peranan 
autoantibodi dan tingkat endotel  proses disfungsi yang dimungkinkan berperan terhadap memberatnya DBD.
Kata kunci: autoimun, dengue, demam berdarah.
ABSTRACT
The immune response of dengue fever/dengue hemorrhagic fever is a series of immunopathogenesis 
processes starting from viral infection to the target on monocytes and macrophages. It may consequently cause 
a cascade of viremia in the circulation that stimulates the afferent, efferent, and effector mechanism by the 
interaction of the humoral and complement system. The cascade results in inflammatory substance that will 
affect capillary permeability and activate coagulation factors leading to further effects on endothelial level. The 
mechanism involving pathogenesis of DHF/DSS is still vague. So far, a theory of heterologous infection has been 
developed, which explains that on second infection, there is subneutralization that induce viral replication. The 
autoimmune mechanism development leads to the better understanding of DHF. It also  explains the autoimmune 
response of the viral infection, which consists of molecular mimicry, bystander activation and viral persistence. 
The development of the autoimmune pathomechanism is related to the role of  autoantibody and endothelial 
dysfunction that may have role in worsening DHF.
Keywords: autoimmune, dengue, hemorrhagic fever.
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INTRODUCTION
Dengue Hemorrhagic Fever (DHF) is a 
reemerging disease that has a long history 
associated with a fluctuation of mortality and 
morbidity. Surveillance and epidemiological 
approach indicate that preventive efforts of the 
upstream sectors have become a priority that 
should be maximized. DHF epidemic in an 
area has become a great concern of Community 
Health experts and clinicians. They evaluate the 
epidemic with community approach to prevent 
further transmission.1
The course of “mysterious” DHF refers to 
various clinical spectrums that develop during 
hospitalization. So far, it has become a great 
concern for the experts, i.e. there are different 
clinical conditions with different output of 
improvement. For example, a patient with a 
stable hemodynamic condition, subsequently 
has  hematemesis and dengue encephalopathy; 
while another patient with pulmonary edema 
and massive pleura effusion, but with a maximal 
conservative treatment, the patient can have a 
good recovery.2
In the management of Dengue Hemorrhagic 
Fever, there is a principle of  “everything can 
happen”. It is inseparable from the principle of 
host-agent-environment, in which the specific 
process of virulence and mechanism in the host 
is induced by environment that has experienced 
different immunological changes or has individual 
variation. Therefore, the management of DHF 
is an art, which is based on pathogenesis and 
pathophysiology approach followed by continuous 
learning of the developed various cases.3
This manuscript is aimed to have a deep 
discussion on the developing pathogenesis and 
pathophysiology of DHF and to evaluate the 
immunopathogenesis process associated with 
autoimmune mechanism.
FROM CLINICAL TO PATHOGENESIS 
SPECTRUM
The pathogenesis spectrum of DHF starts 
from the clinical course of DHF in a measureable 
process. When we evaluate the clinical course 
of DHF based on 2009 WHO guideline, we can 
see three phases, i.e. the febrile, critical and 
recovery phases. Those three phases describe a 
natural process of viral infection, i.e. in febrile 
phase, there is viremia; while the critical phase is 
a characteristic of dengue virus causing plasma 
leakage and in recovery phase, immune response 
and endothelial improvement have a role, which 
is consistent with improved clinical condition.4-7 
(Figure 1) 
There are some theory that have been 
developed about the pathogenesis of DHF so 
Figure 1. Clinical course of dengue hemorrhagic fever7
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far, i.e. (1) Primary infection theory (theory 
of virulence), (2) Secondary infection theory 
(immunopathology theory), (3) Antigen antibody 
complex theory, (4) Theory of infection enhancing 
antibody, (5) Mediator theory, (6) Theory on 
the role of endotoxin, (7) Theory on the role 
of lymphocytes, (8) Theory of thrombosis, (9) 
Theory of apoptosis.5,6
The secondary infection theory has a risk 
for developing severe infection. The theory of 
antigen antibody complex is characterized by 
reduced level of C3, proactivator C3, C4 and 
C5, which are the markers of severe DHF. The 
resulted C3a and C5a anaphylatoxins are strong 
mediators for increased capillary permeability 
that may lead to plasma leakage. The theory 
of infection enhancing antibody is based on 
the phagocytic role of mononuclear cells and 
the development of non-neutralized antibody. 
The virus has attack target, i.e. on phagocytes 
such as macrophages, monocytes and kuppfer 
cells. The infected macrophage will be activated 
and releases various inflammatory substances, 
cytokines and thromboplastin that affect capillary 
permeability. Moreover, the role of endotoxin is 
based on the role of shock in DHF that causes 
intestinal ischemia in addition to ischemia of 
the tissues. At that time, bacterial translocation 
can occur from the intestinal lumen into the 
circulation. Endotoxin, which is the component 
of outer capsule of negative-gram bacteria, 
enters the circulation through activation of 
cytokines cascade. It leads to shock followed 
with severe ischemia. The role of lymphocytes 
is based on the activated lymphocytes on the 
macrophages, which are exposed to the virus. It 
releases lymphokines, activates B cells therefore 
the amount is greater in DHF/DSS. The last 
theory is the theory of apoptosis, which is based 
on the physiological process of cell death. The 
process consists of two phases, i.e. the damage 
of cell nuclear and changes in cell form and 
permeability of cell membrane. In severe DHF 
with severe liver damage, Councilmen bodies 
can be found.6
CLINICAL SPECTRUM OF WARNING SIGN 
ON IMMUNOPATHOGENESIS
The 2009 WHO guideline describes that 
there is a clinical spectrum of warning sign 
such as abdominal pain, persistent vomiting, 
fluid accumulation, mucosal bleeding, liver 
enlargement and increased hematocrit along 
with reduced platelet count. The warning sign 
is a clinical process, which is a manifestation of 
a complicated immunopathogenesis process.7
The warning signs in DHF indicate 
progressive course of immunopathogenesis of 
viral infection on vascular changes, target organ 
and changes at endothelial level. If it is not 
managed well, it may result in plasma leakage, 
bleeding, organ dysfunction, which are the 
Figure 2. Classification and the severity of dengue cases7
Without
With warning
signs
1. Severe plasma leakage
2. Severe haemorrhage
3. Severe organ impairment
DENGUE WARNING SIGNS+ SEVERE DENGUE
CRITERIA FOR DENGUE WARNING SIGNS+ CRITERIA FOR SEVERE DENGUE
Probable dengue
Live in/travel to dengue-endemic area
Fever and two of the following criteria:
- Nausea, vomiting
- Rash
- Aches and pains
- Tourniquet test positive
- Leucopenia
- Any warning sign
Laboratory-confirmed dengue
(important when no sign of plasma leakage)
Warning signs*
- Abdominal pain or tenderness
- Persistent vomiting
- Clinical fluid accumulation
- Mucosal bleed
- Lethargy, restlessness
- Liver enlargement >2 cm
- Laboratory: increase in HCT concurrent
with rapid decrease in platelet count
* (Requiring strict observation and medical
intervention)
Severe plasma leakage
Leading to:
- Shock (DSS)
- Fluid accumulation with respiratory
distress
Laboratory-confirmed dengue
as evaluated by clinician
Severe organ involvement
- Liver: AST or ALT 1000>
- CNS: Impaired consciousness
- Heart and other organs
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criteria of severe dengue. Warning signs actually 
should be treated as the emerging clinical process 
on the surface along with a good understanding 
on the ongoing immunopathogenesis process.7  
As we have known, the female mosquito of 
Aedes aegypti bites human and injects virus into 
the circulation. The dengue virus is later attached 
to monocytes through receptor factor and it 
enters the monocytes.3,8 In this condition, there 
is an afferent mechanism, in which the virus has 
been developed through union and attachment of 
several segments of the genes and therefore, the 
receptor factor is developed. Subsequently, the 
efferent mechanism occurs, i.e. the monocytes 
containing virus are distributed to liver, spleen, 
intestines and bone marrow; thus, viremia occurs. 
In the next step, there is an effector mechanism, 
in which the infected monocytes will have an 
interaction with various humoral systems such 
as complement system by releasing inflammatory 
substances, cytokines and thromboplastin that 
will affect capillary permeability and activates 
coagulation factors.8
Another approach suggests that the dengue 
virus will attack macrophages and it will replicate 
in the langerhans cells and macrophages of the 
spleen. Furthermore, it stimulates the T cells 
arrangement, cross reactivity of T cells with 
low avidity and cross reactivity of specific T 
cells, which will increase the production of 
specific and cross reactive antibodies.9 In the 
next phase, there is a simultaneous cross reaction 
between antibody and platelets as well as cross 
reactivity between plasmin and specific product. 
The process will then further increase the role of 
antibody in increasing virus titer and on the other 
hand, there is a cross reaction of antibody and 
endotheliocytes. Next, there is replication effect 
inside the selective endotheliocytes; therefore, 
apoptosis occurs resulting in endothelial 
dysfunction. Meanwhile, stimulation of soluble 
mediators also occurs, i.e. the TNFa, IFNg,  IL-1, 
IL-2 , IL-6, IL8, IL-10, IL13, IL18, TGFb, C3a, 
C4b, C5a, MCP-1, CCL-2, VEGF, NO, which 
causes imbalanced profile of cytokines and other 
mediators that subsequently causes coagulation 
disorder and endothelial dysfunction.9
In the liver, replication will occur in the 
hepatocytes and kuppfer cells. Necrosis and/or 
apoptosis occur, which reduces liver function, 
releases toxic product into the circulation, 
increases coagulation function, increases platelet 
consumption, activates the fibrinolytic system 
and causes coagulation disorder.9 Dengue virus 
that attacks macrophages in the hepatocytes is 
characterized by hepatitis (increased SGOT and 
SGPT), apoptosis, overproduction of IL-6 and 
oxidative stress that may result in RANTES.10 
Endothelial damage is initiated by viral 
intervention on monocytes that causes excessive 
cytokine production and inversed ratio of CD4/
CD8. The excessive cytokine production and 
IL-6 will stimulate the development of atypical 
lymphocytemia that activates platelets, Anti DV 
Ab, anti platelet autoantibody (Anti NS1 Ab) 
and Anti EC Antibody. The virus also attacks 
neutrophil that may lead to bandemia. Through 
abnormal activity, it causes CD 69 excretion, 
reduced CD4/CD8 ratio and excessive cytokine 
production. The process causes endothelial 
damage, which is characterized by apoptosis, 
release of thrombomodulin, IL6, IL8, RANTES, 
reduced tPA/PA1 ratio, ICAM expression, cell-
mediated damage (PMC,PBMC), antibody-
mediated damage (Anti DV Ab, Anti Ec Ab) and 
complement activation.10
Bleeding as a warning sign is caused by three 
major hemostasis disorders, i.e. vasculopathy, 
platelet disorder and reduced serum level of 
coagulation factors. At the initial phase of 
fever, the bleeding is caused by vasculopathy 
and thrombocytopenia; while in the shock and 
prolonged shock phase, the bleeding is caused 
by thrombocytopenia, which is followed by 
coagulopathy, particularly due to disseminated 
intravascular coagulation (DIC) and increased 
fibrinolysis. The clinical manifestations of 
vasculopathy are petechiae, positive result 
of Rumple Leed test, plasma leakage as well 
as electrolyte and protein leakage into the 
extravascular cavity. The major etiology of 
vasculopathy is the release of C3a and C5a 
anaphylatoxin.8,11
At the initial phase of the disease (the 1st 
up to 4th day), reduced platelet production is 
the cause of thrombocytopenia. At that time, the 
bone marrow appears to have mild hypocellular 
state and there is increased megakariocytes in 
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various types of maturation. The virus directly 
attacks myeloid and megakariocytes. The platelet 
count at that time may reach 20,000 – 50,000/
mm3. On the 5th to 8th day, thrombocytopenia 
occurs particularly due to platelet destruction in 
the circulation. The attached immune complex 
on the surface of platelet facilitates platelet 
destruction through reticuloendothelial system in 
the liver and spleen that causes thrombocytopenia 
in the shock phase. Platelet destruction is also 
caused by endothelial damage, immune complex 
reaction, specific platelet antibody or DIC due to 
prolonged shock. In this phase, there is increased 
number of megakariocytes in the bone marrow. 
The PAF release may be due to platelet and 
monokine activation. Simultaneously, increased 
PAF level as well as TNFa, IL-1, IL-6, IL-8, 
C3a, C5a and histamine causes endothelial 
malfunction of the capillaries and therefore, 
plasma leakage and hypovolemic shock occur.8,11
By evaluating the above mentioned 
discussion, it is clear that the clinical descriptions 
of warning signs in DHF are actually an iceberg 
phenomenon, i.e. there is a relatively complicated 
ongoing immunopathogenesis process  and we do 
not know whether it will be more severe or not. 
AUTOIMMUNE MECHANISM OF DHF
Autoimmune mechanism of DHF is a 
pathomechanism process that so far has been 
tried to provide answers on the mechanism of 
various clinical variations and various severity 
problems in the clinical domain. A study by 
Falconar explains that autoimmune response of 
DHF infection consists of molecular mimicry, 
bystander activation and viral persistence. 
Using animal experimental study, it shows that 
DEN-V NS1 antibody causes cross reactivity 
with coagulation protein in human as well as 
with integrin/adhesion protein, endothelial 
cells and platelets. Subsequently, the cross 
reactivity of DENV-NS1monoclonal antibody 
causes bleeding.13 The study also reveals that 
antibody in the serum of dengue patients has 
cross reactivity with endothelial cells. The 
antiplatelet serum level and autoantibody of 
endothelial cells of patients with DHF/DSS 
are higher than patients with Dengue fever. 
Therefore, the experimental study demonstrates 
that anti DEN V NS1 antibody has partial cross 
reactivity and apoptosis with endothelial cells. It 
is also associated with platelet autoantibody and 
the anti DEN V NS1 activates inflammation in 
the endothelial cells. In this case, the molecular 
mimicry occurs between the component of 
dengue virus and the elements of platelets and 
endothelial system.13 Another study suggests 
a hypothesis on autoimmune mechanism that 
causes symptoms of DHF and the NS1 protein 
releases molecular structural mimicry that 
resembles human platelets, endothelial cells 
and coagulation protein. The level of antibody 
is increased in experimental rats and the DEN V 
NS1 has cross reactivity with epitopes mimetic of 
human platelets and endothelial cells; therefore, 
the platelet life is shorter and it increases vascular 
permeability in the in vitro system.11
MOLECULAR MIMICRY AND BYSTANDER 
ACTIVATION
I n  t h e  d e v e l o p m e n t  o f  D H F 
immunopathogenesis, there is an excessive 
immune activation and cytokine production 
affecting the monocytes, endothelial cells and 
hepatocytes as well as abnormal production 
of autoantibody against endothelial cells and 
platelets. It causes disruption of immune 
response in clearing virus including changes in 
CD4/CD8 ratio.
Moreover, the molecular mimicry occurs 
between endothelial cells/platelets and antigens 
of dengue virus. Platelets and endothelial cells 
are bound by cross reactive antibody of anti 
dengue virus such as the anti NS1 or the anti prM 
antibody. IFNg activates macrophages to perform 
phagocytosis of opsonin target. The autoantibody 
then will initiate cell dysfunction. IFNg activates 
macrophages that phagocytes the autoantibody 
covering the platelets and endothelial cells, which 
results in thrombocytopenia and endothelial cell 
damage. The short-term hemophagocytic activity 
is caused by post-acute infection of dengue 
virus.12
So far, there are some mechanisms explaining 
autoimmune response against viral infection. 
Among the newest mechanisms that explain 
autoimmune response by viral infection are 
molecular mimicry, bystander activation and 
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viral persistence. Antibody against plasminogen 
peptide can be detected in 70% serum of patients 
who have acute phase in Thailand. Similar 
findings are also found in Tahiti, in which similar 
antibody is detected and correlated to secondary 
infection and bleeding. A study in Thailand shows 
that the serum of patients who have convalescent 
phase for 1-4 months in 16 patients with Dengue 
Fever has actually responded to 759-799 human 
plasminogen peptide and has moderately reduced 
the activity of serum plasmin.13,14
A U T O I M M U N E  R E A C T I O N  A T 
ENDOTHELIAL LEVEL
A study mentioned by Chiou FL (2003)  has 
found a cross reactivity between the serum of 
dengue patients and endothelial cells. There are 
higher percentages of endothelial cell reaction 
in DHF/DSS than DF. The higher percentage 
of endothelial cell reaction against Ig M is also 
higher compared to against Ig G. The study 
demonstrates that the activity of endothelial cell 
binding and serum of dengue patients, which 
induces apoptosis of endothelial cells through 
caspase – dependent pathway, is inhibited by 
NS1 pre treatment. The presence of antibody 
against NS1 production following the infection 
of dengue virus explains cross reactivity between 
the serum of patients and endothelial cells. The 
study concludes that the cross reactive antibody 
against endothelial cells indicates that there is a 
dysfunction that may have a role in pathogenesis 
of dengue infection.15
The study by Chiou FL demonstrates that 
there is an antibody against non-structural NS1 
protein of dengue virus, which is originated 
from rat and it has cross reactivity with human 
endothelial cells and vascular endothelium. 
After there is an endothelial binding by the anti 
NS1 antibody, it causes apoptosis of endothelial 
cells on the caspase dependent pathway. In this 
process, the capacity and the expression outcome 
of NO synthesis (iNOS) are observed. The 
addition of NO synthetase inhibits the protection 
from anti NS1 and induces apoptosis. The 
apoptosis of endothelial cells is characterized 
by serin phosphatidyl on the cell surface and 
fragmentation of DNA nucleus, which is blocked 
from the treatment using inhibitor synthetase N 
nitro L arginine methyl ester. Further studies 
describe that the expression of Bcl2 and Bclx are 
reduced, both on the mRNA and protein level, 
which is characterized by increasing p53 and 
Bax following the treatment using anti NS1. The 
study evaluated the release against cytochrome 
and the effect due to inhibition by N nitro L 
arginine methyl ester. Based on the study, it can 
be concluded that anti Ns1 Ab is an autoantibody 
that has cross reactivity with the uninfected 
endothelial cells by inducing intracellular signal 
Figure 3. Immunopathogenesis of DHF12
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that lead to NO production and apoptosis. Cell 
damage and endothelial cell apoptosis may be 
related to disruption of endothelial barrier that 
causes transient vascular leakage in dengue 
vasculopathy and it has some contribution in the 
pathogenesis of dengue diseas.16
A study by Chungue (1994) suggests an 
analysis that although most of dengue fever can 
have complete recovery, but plasma leakage 
may be important factor for severe dengue 
into DSS. In the study, it is stated that the 
development of antibody and cross reactivity 
against plasminogen has been reported to have 
a high percentage in Thailand patients with DF 
and DHF/DSS. The correlation between the 
detection on plasminogen cross reactive antibody 
and bleeding has been evaluated in 88 children in 
Tahiti who had type 3 dengue virus. The results 
show that there were 59 children with and 29 
children without bleeding. The plasminogen 
cross reactive antibodies were found in acute 
and convalescent serum and the antibodies were 
parallel to the cross reactivity on protein E of 
dengue virus. The antibodies are more commonly 
found in children with secondary infection than 
those with primary infection. The plasminogen 
cross reactive antibodies is not related to the 
development of DHF/DSS or thrombocytopenia. 
The results are consistent with the possibility that 
plasma cross reactive antibodies have important 
role as the etiology of bleeding in dengue viral 
infection.17
A study by Henchal (1998) demonstrates that 
in non-neutralization, the serotype of specific 
anti NS1 monoclonal antibody has partially 
protected the rats that had been infected by 
the deadly intracerebral dengue virus type 2. 
There is no correlation between the persistent 
complement activity and the protective capacity 
among the individuals on the monoclonal 
antibodies or whether the partial protective 
antibodies results in longer survival or reduced 
mortality. Complete protection, which is 
achieved following the immunization using 
polyclonal neutralization antibody, is reached by 
some individual antibodies and the complement 
increases to high titer using homologous virus. 
Some groups of the rats have increased morbidity 
rate after having immunization with combined 
protection of monoclonal antibodies that bind 
the overlapping epitope. The results may have 
impacts on the design of  recombinant dengue 
vaccine, which may give some inputs of specific 
antigenic domain.18
According to a study by Valde (2008), the 
antibodies against the protein of type 2 and 
type 4 dengue viruses were found in the serum 
of acute phase of 10 patients with primary and 
secondary dengue fever and dengue hemorrhagic 
fever that had been evaluated using western 
blotting technique. In the first group, the immune 
response was almost undetected, while in the 
second group, more protein was detected using 
strong reaction. Anti E, NS3 and NS5 antibodies 
were detected in most cases. The implementation 
is possible for initial diagnostic of antigen 
detection.19
Evaluating the above mentioned discussion, 
we know that immunopathologic mechanism 
has a role in the pathogenesis of DHF. The 
dengue antibodies have been reported to 
mediate three biological functions in vitro, 
which contribute on prevention and controlling 
viral infection, i.e. neutralization, complement-
mediated cytolysis and antibody-dependent cell 
mediated cytotoxicity. The antibody level can 
be increased in dengue viral infection through 
ADE phenomenon. The response of antibody in 
secondary infection is characterized differently 
from the primary infection. The protein of 
dengue virus can stimulate antibody production. 
However, there are only limited studies that have 
evaluated the response characterization to define 
how antibody is correlated to recovery or severity 
of dengue infection. The studies are about the 
definition of immune response on structural and 
non-structural protein. Serum samples were 
taken in 5-7 days since the onset of the disease 
and 20 cases were confirmed serologically. Ig M 
anti dengue were detected in all samples. Serum 
of 5 patients with dengue virus (all with primary 
infection) and 15 patients with DHF (5 with 
primary and 10 with secondary infection) were 
evaluated using western blotting. Monoclonal and 
polyclonal dengue antibodies and the serum of 
non-immune infected dengue patients were used 
as the control. Total immunoglobin of at least one 
or two Den-4 antigen protein was demonstrated 
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in 9 of 90 cases of primary infection (90%). 
No NS1 antibody could be detected in some 
serum of primary infection cases; while 4 of 10 
cases with secondary infection (40%) had NS1 
antibody. The response against the envelope (E) 
and NS5 protein was consistent, both in primary 
or secondary infection. Anti NS3 antibody was 
not detected, either in the primary or secondary 
infection. There was more limited responses 
observed using Den-2 antigen. In contrast, there 
was an extensive response of E antibody only in 
the cases of secondary infection, but the response 
was larger (80%) and more intensive when it was 
observed with Den-4 antigen. Natural dengue 
virus infection in human and potent antibody 
response can be easily measured using some 
serologic tests. The quality of antibody response 
to dengue virus has not been extensively studied 
and it is based on the previous reports. Both 
in primary and secondary infection, the anti E 
Afferent Phase
Effector Phase
Critical Point
Warning sign
Efferent Phase
Infection of Dengue
Virus
Febrile Phase
Dehydration
Hematocrit
changes
Viremia
Receptor Factor
Liver
Spleen
Intesne
Bone Marrow
Viremia
Humoral and
complement
system
Inflammatory Substances
Crical Phase
Hemorrhagic
Shock
Organ dysfuncon
Reduced platelets
Increased
hematocrit
Increased
capillary
permeability
Acvated
coagulaon
factors
Abdominal pain
Persistent
voming
Fluid
accumulaon
Mucosal bleeding
Lethargy
Liver enlargement
Increased
hematocrit and
reduced platelets
Immunopathogenesis
Clinical impacts
Autoimmune
mechanism
Molecular Mimicry
Bystander Acvaon
Viral Persistence
Endothelial
Autoimmune
Reacon
Progressive improvement
Translocaon
bacterial, sepsis
Figure 4. The serial of clinical process and warning signs of DHF along with autoimmune mechanism as an intertwining 
connection.
Soroy Lardo                                                                                                                     Acta Med Indones-Indones J Intern Med
78
antibody are more commonly detected. This 
fact is probably correlated to the role of protein 
E, i.e. the surface of major protein and viral 
antigen is essential in biological terminology 
of virus, humoral immunity and protection. It is 
interesting to be noted that in the study that there 
is a response of NS 5 on non-structural protein 
with polymerase activity. Some authors have 
reported a significant antibody response to NS3 
protein, both in primary or secondary infection.19
C O N N E C T I N G  T H E  A U T O I M M U N E 
MECHANISM AND CLINICAL IMPACTS
Autoimmune mechanism in DHF is certainly 
expected to open the isolated knowledge in 
understanding the process and pathogenesis of 
DHF. Deep discussion on this issue will bring 
some understanding points that can be a reference 
when we deal with severe dengue hemorrhagic 
fever. It includes how to understand a clinical 
process and warning signs of DHF along with 
autoimmune mechanism as an intertwining 
connection. The serial of process can be 
described in the Figure 4.
CONCLUSION
Dengue Hemorrhagic Fever is a reemerging 
disease and the clinical course is through febrile 
phase (viremia) by activation of inflammatory 
cytokines – critical phase, which is characterized 
by increased capillary permeability and organ 
dysfunction as the warning signs and recovery 
(improvement) phase. The clinical course of 
warning sign is a form of clinical manifestation 
of the ongoing immunopathogenesis process 
including an autoimmune mechanism process 
characterized by pathomechanism at endothelial 
level, i.e. molecular mimicry, bystander 
activation and viral persistence. The autoimmune 
mechanism with different grades and spectrums 
determines whether a DHF infection can have a 
recovery or worsen condition.
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